Efficacy and safety of letrozole in treatment of male children with disorders of sex development.
10.3785/j.issn.1008-9292.2020.04.06
- Author:
Bingqing YU
1
;
Min NIE
1
;
Xueyan WU
1
;
Jiangfeng MAO
1
;
Xi WANG
1
;
Wanlu MA
1
;
Wen JI
1
;
Qibin HUANG
1
;
Rui ZHANG
1
Author Information
1. Department of Endocrinology, National Health Commission Key laboratory of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Child;
Disorders of Sex Development;
drug therapy;
Follicle Stimulating Hormone;
Humans;
Letrozole;
therapeutic use;
Luteinizing Hormone;
Male;
Retrospective Studies;
Testosterone
- From:
Journal of Zhejiang University. Medical sciences
2020;49(3):297-301
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of aromatase inhibitor letrozole in treatment of male children with disorders of sex development (DSD).
METHODS:Clinical data of 12 male DSD children with a mean age of 14.6±2.5 years admitted to Peking Union Medical College Hospital from January 2014 to January 2016 were retrospectively analyzed. The patients were treated with letrozole (1.25-2.5 mg, once a day) for 3 months or longer, and followed up for 0.5-2.5 years. Clinical manifestation and laboratory test findings were documented, and the efficacy and safety were evaluated.
RESULTS:After half-year treatment, the blood luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone levels of patients increased (all < 0.05), and estrogen levels decreased from baseline ( < 0.05). After 1 year of treatment, the blood testosterone level was significantly higher ( < 0.05); the LH and FSH levels tended to increase and the estrogen level tended to decrease, but there was no significant statistical difference ( >0.05). Semen was routinely detected in 8 patients, and sperms were detected in semen of 3 patients with hypospadias. There were no significant changes in biochemical results after treatment, and no significant adverse event was observed during the treatment.
CONCLUSIONS:Letrozole can effectively increase testosterone levels in patients with disorders of sex development and promote spermatogenesis, it has no significant adverse effects in short-term administration.
